Created On: 2020-07-15
Record Count: 4
- Diagnostic Substances
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 4400
(i) in vitro therapeutic test system that uses cultured human fibroblasts or any other method to detect and measure PKC and/or other assays with peripheral cells to predict the presence of Alzheimerâ€™s Disease in humans, and all succeeding test formats (including test kits);
(ii) the PKC activators (including bryostatin, analogs, PUFAs, and other PKC activators) and their therapeutic applications in humans or animals;
(iii) the LDL or ApoE-based drug delivery system that is targeted to enhance access of all manner of drugs and therapeutics to the brain by facilitation of transport of such drugs across the Blood-Brain-Barrier in humans or animals; and
(iv) the carbonic anhydrase activators and their therapeutic applications in humans or animals
Effective August 28, 2013, licensee signed a statement of work (SOW) with licensor pursuant to the License Agreement, whereby the Company has contracted for the further development of its AD diagnostic product. The project is intended to validate each of three biomarkers in a heterogeneous patient population to determine sensitivity and selectivity parameters for each biomarker, or combination of biomarkers, to detect Alzheimerâ€™s Disease. The three biomarkers to be evaluated are: the PKCe levels, the Erk1/2 ratios, and the fibroblast morphology test.
IPSCIO Record ID: 6572
IPSCIO Record ID: 27678
Diagnostic Field The field of diagnostics, specifically, biomarker analytical assays for human diagnostic, theranostic or prognostic use.
Methods for detecting and modulating the sensitivity of tumor cells.
IPSCIO Record ID: 29096
The Licensor Licensed certain patents related to UGT1A1, from a University pursuant to a License Agreement dated November 18, 2005.
US Issued Pat App No. 08/423,641, filing date 04/17/95, Patent No. 5,786,344
US Issued Pat App No. 09/251,274, filing date 02/16/99, Patent No. 6,395,481
US Issued Pat App No. 10/061,693, filing date 02/01/02, Patent No. 6,472,157